Article in Journal of medical primatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 4 institutions in 2 countries.
Alexis A GonzalezInstuto de Química Pontificia Universidad Católica de Valparaíso, Valparaiso, Chile.
Emily L OlsenDepartment of Microbiology & Immunology, Tulane School of Medicine, New Orleans, Louisiana, USA.
Stephanie Z KilleenTulane National Primate Research Center, Covington, Louisiana, USA.
Robert V BlairTulane National Primate Research Center, Covington, Louisiana, USA.
Surya V SeshanDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.
Edgar A JaimesRenal Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Chad J RoyDepartment of Microbiology & Immunology, Tulane School of Medicine, New Orleans, Louisiana, USA.ORCID 0000-0002-1710-6974
Minolfa C PrietoDepartment of Physiology and Tulane Renal Hypertension Center of Excellence, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Tulane University · USCornell University · USMemorial Sloan Kettering Cancer Center · USPontificia Universidad Católica de Valparaíso · CL
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Nanotechnology as a therapeutic approach in arteriovenous fistula maturationR01DK129299 · NIDDK · UNIVERSITY OF UTAH · PI JAIMES, EDGAR A, SHIU, YAN-TING E. · 2021 to 2024
$1.7M
Renal tubule-specific nanotherapeutics for acute kidney injuryR01DK114321 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN, JAIMES, EDGAR A · 2018 to 2020
$796k
COVID-19 and Kidney Injury: Urinary Transcriptomics of Kidney Injury in Novel Nonhuman Primate Models of SARS-CoV-2R21AI164232 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI PRIETO, MINOLFA C · 2022 to 2023
Increases of soluble urokinase plasminogen activator receptor (suPAR) were measured in both urine and plasma of a Chlorocebus aethiops (African green monkey; AGM) mucosal infected with SARS-CoV-2. The data indicate that elevated suPAR may be associated with renal dysfunction and pathology in the context of COVID-19.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Elevated soluble urokinase plasminogen activator receptor is associated with renal dysfunction in a Chlorocebus atheiops COVID-19 model. · full record | OpenQuestion